Search results
Cramer's Lighting Round: ‘You've got a winner' with Astra Zeneca
NBC Los Angeles· 7 days ago“Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to...
Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 1 day agoIn the first quarter, Wainua royalty revenues were $1 million. Wainua generated sales of $5 million...
Women denied ‘wonder drug’ that could double terminal breast cancer life expectancy
Daily Telegraph· 4 days agoWomen with HER2-low or ultra-low breast cancer who took Enhertu lived without their cancer growing...
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
MedPage Today· 6 days agoThe antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved...
Lung cancer treatment produces progression-free survival results in Phase III trial
Medical Xpress· 2 days agoOsimertinib, produced by AstraZeneca under the brand name Tagrisso, significantly extends the time patients live without their cancer worsening, offering the first effective ...
AstraZeneca PLC ADR TradeGate Stock Price Today | NASDAQ AZNPy Live Ticker - Investing.com
Investing.com· 2 days agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
Veeva R&D Summit: Pharma companies need a say in AI regulation
Clinical Trials Arena via Yahoo Finance· 1 day agoSenderovitz is working with partners from other pharmaceutical companies, including James...
Astra’s Enhertu delays breast cancer in patients with low HER2 levels
WSAU Wausau· 5 days agoBy Deena Beasley (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to...
World-First Trial Shows Benefits of Finding, Treating Undiagnosed Asthma, COPD
MedPage Today· 2 days agoIdentifying symptomatic individuals in the community with undiagnosed asthma and chronic obstructive...
'Outstanding' Results for Osimertinib: Stage III EGFR+ NSCLC
Medscape· 4 days agoResults from the LAURA trial will change practice once its label gets expanded, experts said at the...